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SUMMARY
. The specificity of tissue thromboplastin towards factor vII is such that, with
bovine thromboplastin, unactivated human factor VII will not show.up in a one-stage
test. This property ls used to develop a test which is specific for activated factor vII'
INTRODUCTION
Bloodcoagulat ioncanbetr iggeredbymater ial f romwoundedt issue.These
materials are called tissue thromboplastins. They comprise at least a phospholipid
andaproteincomponent,intimatelylinkedtogether.Thromboplastinactivatesthe
plasma protein factor vII. Activated factor vII converts the proenzyme factor X
into its inzymatically active form (factor X6). Factor Xa and factor V adsorb onto a
phospholipid-water interface and thus form the prothrombin activating enzymel'
combination of factor vII with (components from) tissue thromboplastin is an
essential part in the generation of factor X converting activityz-a' There are many
iral"",i"i, that combination of factor vII with tissue lipoproteins is not the sole
fro".r, leading to such an activity. Changes in the factor VII molecule 
seem to play
a role us well. under various experimental conditions excluding a reaction between
factor vII and tissue lipoproteins, factor vll can still become'more activeina coag-
ulation assay. such u 
"ttung" 
in reactivity will be called activation' Activation has
been demonstrated by the action of factor XII (ref. 5), by the action of the kinin
systemo and during purification procedures?'
f thasbeendemonstratedthatact ivatedfactorVl lcanbeinhibi tedbyserine
esterase inhibitorss, whereas plasmatic factor VII is not' It is conceivable that' in
analogy to the factors lX anJ X, factor vII plays its biological role when forming
part Ja lipid-protein complex but also has to be converted from a proenzyme (factor
VII) into an enzyme (factor VII,)g' When this is true, tissue thromboplastin would
F:.{4r-atr , i . l
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not only catalyze the proenzyme-enzyme conversion (activate factor VII) but also
provide lipoproteins which combine with the activated factor VII so as to form a
factor X activator. For a further study of these problems it would be most useful to
be able to estimate the activated but uncomplexed form of factor VII and the unacti-
vated form seParatelY'
There is a well founded practical interest in studying the level of activated factor
VII in the circulation as well: atherosclerotic lesions offer to the circulating plasma
both a foreign surface and a damaged tissue. lt is conceivable therefore that these
lesions activate circulating factor vII. The fraction of factor vII that circulates in its
activated form then would be an indication of the extent of rhe lesions. The first event
in the generation of thrombin by a lesion could be the local concentration of factor
VII* surpassing a critical threshold. The concentration of factor VII' in the circulation
could therefore be an indication of the risk of thrombosis'
MATERIALS AND METHOD' 
..,. 
.
Bovine blood was obtained by jugular venapuncture from normal cows and
collected on citrate (final concentration of l0 mM). The blood was centrifuged (10
min, 3000 x g), the plasma collected and again centrifuged (30 min' 12'000 x g) to
bring <lown the'remaining platelets- Bovine brain thromboplastin was prepared in a
way'completelyanalogoustothePreParationof lffi;:T.'l j:::rt::lf ::'f ff :f;ing to Owren and Aas10. All other materials z
12.
RESULTS
. Table I shows the coagulation times obtained when dilutions of human or
bovine plasma are used as a source of factor VII in a factor Vll-deficient medium'
TABLE I
FAcroR VII orrtnurrunrloN IN HUMAN' BovINE AND cRossED sYsrEMs
Coagulation times obtained with human or bovine plasmas and human or-bovine thromboplastins
(thr. pl.) in a reagent specific for factor vII containing 27 /"httman factor X, 301 bovine factor ^ v'
3ly.humao,factor rr ano1.i mg/ml factor I. The figuris areihe means of 32 estimations. S.D' < I %'
.l
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Plasma concentralion Coagulation times (sec)
( % vlv) Human plasma Bovine plasma
Human thr. pl. Bovine thr. Pl. Human thr. pl. Bovine thr. Pl.
t 0
5
3.3
2.5
2.O
30.8
35.8
38.8
41.5
43.3
87.4
66.7
73.1
74.2
78,7
75.0
62.6
69.9
73.1
72.8
72.4
34.2
43.8
50.4
55.3
59.9
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TABLE II .
FAcroR X ortrnulultloN lN HUMAN, BovlNE AND cRossED sYsrEMs
Coagulation times obtained with human or bovine plasmas and human or bovine thromboplastins
(thr. pl.) in a reagent specific for factor X containing 33Y"human factor VIl, 55f bovine factor
V,24% human factor ll and 1.4 mg/ml factor I. The figures are the means of 32 estimations. S'D.
<  t % .
Plasma concentration
( % vlv)
Coagulation times ( sec)
Human plasnn Bovine plasma
Human thr. pl. Bovine thr. pl. Human thr. pl. Bovine thr. pl.
10
5
3.3
2.5
!
28.2
34.0
36.1
39.3
41.6
72.8
69.2
75.6
77.0
79.5
79.9
97.8
35.0
42.3
46.4
49.6
51.7
36.8
47.9
52.0
55.5
57.6
with either bovine or human thromboplastin. Coagulation times slightly shorter than
the buffer value are obtained when, plasma and thromboplastin come from heterolo-
gous sources. Table II shows that the same is not true for a factor X-deficient system.
Apparently only the heterologous ystem consisting of human thromboplastin and
bovine plasma does not work here; whereas short coagulation times are observed
wrth bovine thromboplastin and human plasma'
Thromboplastin in this type of test serves at least a double purpose. With
factor VII it forms the factor X activator and it provides the lipid-water interface
necessary for the formation of prothrombinase from the factors Xa and Va (ref. 9).
The latter function obviously is not species specific as it can be carried out even by
synthetic or plant phospholipids; it thus seems that heterologous thromboplastin
can function in this stage. The fact that bovine thromboplastin gives long clotting
times with human material would then mean that it cannot readily interact with
human factor VII. Whether the activation step or the combination step fails cannot
be decided from these experiments. The possibility exists that human factor VII, that
has already been activated by means other than reaction with homologous thrombo-
plastin, will still combine with bovine tissue thromboplastin so as to form a factor
X activator. To test this hypothesis we carried out the following experiments.
Normal human plasma - containing normal unactivated factor VII - is in-
cubated with low concentrations of either human or bovine thromboplastin. The
mixture is then subsampled into a factor VII test as described in Table I with the use
of either human or bovine thromboplastin. When no calcium ions are added to the
incubation mixture, no activation is observed. With l0 mM Caz+ added, the incuba-
tion mixture coagulates in approximately 3 min. We therefore sought the Caz+ con-
centration that made the mixture coagulate in about 2 h. This appeared tobe7.5 mM.
The results are shown in Figs. I and2.lncubation with bovine thromboplastin under
no circumstances gave rise to enhanced factor VII activity. Incubation with human
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Fig. I ' Estimation of activated factor VII in the course of coagulation. Test mixture: 0.1 ml bovinethromboplastin' 0.1 ml factor vll-deficient plasma, 0.1 ml sample, 0.1 ml caCle (it mu).Incubation
mixture: normal human citrated plasma. CaCle to 7 .5 mM, 1 % (v lv) of a thromboplastin preparation(c.4. blank). l, human thromboplastin; O, bovine thromboplasiin; O, tlunt tpfichaelis buffer).The vertical dotted line indicates the moment of coagulation in the incubation mixture.
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Fig. 2. Estimation of 'total' factor VII in the course of coagulation. Test mixture: 0.1 ml humanthromboplastin,0.l ml factor vll-deficient plasma,0.l ml sample, o.r mr caci, i:3 mM).Incubationmixture: normal human citrated plasma. caclz to 7.5 mM,l%(vlv)of a thromboplastin preparation(c.4. blank). l, human thromboplastini O, bovine thromboplasiini O, blank (Michaelis buffer).The vertical dotted Iine indicates the moment of coagulation in the incubation 
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thromboplastin caused a slow activation in both test systems. The increase in activity
was much more obvious in the test system in which bovine thromboplastin was used
than in the human system.
It has been reported that factor VII is activated by incubation without thrombo-
plastin in the cold6. This activation in a random normal plasma is an inconstant
phenomenon. lt can be evoked by the generation of plasmin (r.e. urokinase and
plasminogen) and inhibited by Trasylol (Figs. 3 and 4). Again, the activation is much
more obvious when factor VII tests are carried out with the use of bovine thrombo-
plastin than with human thromboplastin (Fig. 3).
DISCUSSION
The experiments how that bovine thromboplastin is hardly able to interact
with human factor VII unless this factor has been previously activated. Bovine
21 (g 12 Vt
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Fig. 3' Estimation of activated factor VII in the course of 'cold promoted activation'. Test mixture:0.1 ml bovine thromboplastin, 0.1 ml factor Vll-deficient plasma, 0.l ml sample, 0.1 ml cacle (33
mM). Incubation mixture: normal human citrated plasma with thefollowingadditions. ---, none;
!,urokinase(a000U/ml) and Trasylol (l0U/ml); [,urokinase (4000Uiml); O, urokinase (4000Uiml) and plasminogen (0.1 mg/ml). The incubation was carried out at 4 "C.
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Fig' 4' Estimation of 'total' factor vII in the course, of cold promoted activation. Test mixture:0'1 ml human thromboprastin, 0.1 ml f;;;vli-d"fi"i"nt prurri", o.i ,or ,".pr", 0.r ml cacrz (33mM)' Incubation mixture: normal human citratJprasm; ;ilt ,h" i"il"wing aooitions. _ _ _, none;l, urokinase (4000 u/mr) and rrasvror iio ;r*-1,.-;;*,ffi Affi/d: o, urokinase (4000U/ml) and plasminogen (0.1 mg/ml-1. fil ir""-U"iiri, was canied out at 4.C.
thromboplastin can therefore be used to estimate the level of activated factor vII inhuman plasma samples. From Tables I and II (summarized in Table III) it is seen thatbovine thromboplastin acting on human factor vII does not cause coaguration timesto shorten appreciably. Neither does human thromboplastin interact with bovinefactor vII. In Table II the data appear as if a reaction is observed with bovine throm_boplastin and bovine factor X, using a human factor X reagent, i.e. human factorvII. one soon realises however that, with the dilutions or "nor-ar bovine plasmameant to be a source of factor X, one adds at the same time bovine factor vII. onethus carries out a combined bovine vII-x estimation. Estimations of the apparentKm according to Hemkerlr (i.e. the concentration of the rate_limiting coagulationfactot at which half-maximal reaction velocity is observed under the conditions ofthe test) showed that although bovine factor VIIa does activate human factor X,the interaction between these proteins is much less efficient (K*: lg.O%)than the
+
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TABLE III
SUMMARY oF TABLES I lllo ll
H, human; B, bovine; H*B indicates that with the excess of human factor in the reagent, a smatl
amount of bovine factor is added with the sample. (B) indicates that the presence of bovine factor
is not thought to be essential. (*) indicates that a high concentration of the rate-limiting factor causes
a short coagulation time and vice versa, i.e., the system 'works'. 1(- is the percentage of rate-limiting
factor that causes half-maximal reaction velocitv.
Limiting factor Thromboplastin Origin of factor Results Km
VII
B
H
B
H
H
H
H
H
+
+
:
i-
+
+
VII
VII
VII
VII
x
X
x
x
B
B
H
H
B
B
H
H
H
H
H
H
B
H
B
H
+ (B)
+ (B)
18.0
t . t
2-5*
4.O
2.1
+ (B)
* Accurate estimation impossible, because the method of estimation fails.
interaction of homologous coagulation factors (K*: 1.9%).No Kza could be esti-
mated with bovine thromboplastin and bovine sample using a human factor X reagent
as two factors are rate-limiting there. Such a species specificity has been observed by
other authorsl3-l5. The present experiment$ indicate that this specificity does not
reside in the combination of factor VII with thromboplastin but rather in the activa-
tion of factor Vll.
When human plasma is incubated with a small amount of homologous thrombo-
plastin a slow rise in activity is observed. The time course suggests an enzymatic
activation rather than a stoichiometric complexation as the complexation step has
been shown to be very rapid3'4. The increase in activity is very marked when bovine
thromboplastin is used in the test system, suggesting that the factor VII activated by
the human thromboplastin during preincubation combines with the bovine thrombo-
plastin. With the use of human thromboplastin in the test system, an increase in
factor VII activity can still be observed. This can be readily explained by assuming
that the activation step and not the combination step is rate-limiting as would be
expected from the observed kinetics of the combination3,a. Although suggestive of
the idea that activation of factor VII is species specific and combination with the
thromboplastin lipoprotein is not, these experiments lack conviction because an
effect of combination of factor VII with homologous thromboplastin during the
preincubation cannot be ruled out. This is not the case in the experiments shown in
Fig. 3. Here factor VII is activated at 4 "C as described by Gjonnaesso.
The apparent concentration of factor VII, when tested with bovine thrombo-
plastin, is dramatically increased by this type of activation; whereas the increase as
observed with the use of human thromboplastin is much smaller. This again argues
in favour of the idea that activated factor VII is measured with bovine thromboplastin.
it34
When tested with human thromboplastin, previously unactivated factor VII is acti-
vated during the test procedure. This activation is by no means complete, so that the
outcome of the normal one-stage procedure using human thromboplastin is influenced
by the state of activation of factor vII in the plasma. This may b. u rour". of errorin factor VII estimations and it may well be the cause of the reportedly high factor
VII concentration in elderly people. The state of activation of factor VII in a sample
can be assessed by determining the ratio of the factor VII level estimated with bovine
thromboplastin over that estimated with human thromboplastin.
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